Lipitor Payments Under Medicaid Vary By 12% – IG
Some states paid as much as 12% more than the lowest paying states for identical units of Pfizer's Lipitor in fiscal year 2001, a report from the HHS Office of Inspector General concludes
You may also be interested in...
Drug manufacturers may face lawsuits for failing to provide average manufacturer price information to states that have requested it
The HHS Office of Inspector General's report on Medicaid spending for mental health drugs singles out Lilly's Zyprexa (olanzapine) as a particularly costly product for the program
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011